Allspring Global Investments
OBIO icon

Allspring Global Investments’s Orchestra BioMed OBIO Stock Holding History

Allspring Global Investments’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,904
Closed -$42.8K – 2575
2023
Q3 		$42.8K Buy
+4,904
New +$33K ﹤0.01% 2317

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments's OBIO Position: Q4 2023 in Review

Allspring Global Investments sold out of Orchestra BioMed (OBIO) in Q4 2023, closing a stake of 4,904 shares — an estimated $42.8K sold.

Allspring Global Investments first reported a position in OBIO in Q3 2023 and held it in 1 quarter. The position peaked at $42.8K in Q3 2023. 39 funds tracked by Wall St. Rank hold OBIO as of Q4 2023.

  • Allspring Global Investments reported no remaining Orchestra BioMed position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 4,904 Orchestra BioMed shares in Q4 2023, an estimated $42.8K.
  • Allspring Global Investments first reported a position in Orchestra BioMed in Q3 2023 and held it in 1 quarter.
  • Allspring Global Investments's Orchestra BioMed position peaked at $42.8K in Q3 2023.
  • 39 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.